Hsieh Pin-Pen, Tung Chun-Liang, Chan Amy Bik-Wan, Liao Jia-Bin, Wang Jyh-Seng, Tseng Hui-Hwa, Su Hsing-Hao, Chang Kun-Chao, Chang Chung-Che
Department of Pathology & Laboratory Medicine, Veterans General Hospital Kaohsiung, Kaohsiung, Taiwan.
Am J Clin Pathol. 2007 Oct;128(4):579-84. doi: 10.1309/MN4Y8HLQWKD9NB5E.
We retrospectively studied 19 cases of nasal NK/T-cell lymphoma for various potential prognostic factors and performed real-time quantitative polymerase chain reaction for Epstein-Barr virus (EBV) viral load in tumor tissue. Patients with a low EBV viral load (<1 copy per cell) more frequently survived for more than 2 years compared with patients with a high EBV viral load (>/=1 copies/cell) (7/7 vs 3/9; P = .014; Fisher exact test). Furthermore, the patients with low EBV viral loads had a better overall survival than patients with high viral loads (50% accumulative survival: not reached vs 4-5 months; Kaplan-Meier survival analysis; P = .049). In contrast, the overall survival of the patients did not correlate with the extent of lesion, age, stage, necrosis, histologic subtypes, CD56 expression, or angiocentric or angiodestructive growth pattern. Our findings suggest that the EBV viral load in tumor tissues is a useful indicator for predicting outcome of nasal NK/T-cell lymphoma.
我们回顾性研究了19例鼻NK/T细胞淋巴瘤患者的各种潜在预后因素，并对肿瘤组织中的爱泼斯坦-巴尔病毒（EBV）病毒载量进行了实时定量聚合酶链反应。与EBV病毒载量高（≥1拷贝/细胞）的患者相比，EBV病毒载量低（<1拷贝/细胞）的患者更常存活超过2年（7/7 vs 3/9；P = .014；Fisher精确检验）。此外，EBV病毒载量低的患者总生存期优于病毒载量高的患者（累积生存率50%：未达到 vs 4 - 5个月；Kaplan-Meier生存分析；P = .049）。相比之下，患者的总生存期与病变范围、年龄、分期、坏死、组织学亚型、CD56表达或血管中心性或血管破坏性生长模式无关。我们的研究结果表明，肿瘤组织中的EBV病毒载量是预测鼻NK/T细胞淋巴瘤预后的有用指标。
